Posted by Michael Wonder on 01 Feb 2022
Celltrion Healthcare announces Canadian approval of Yuflyma, a high concentration, low volume, citrate free and latex free Humira (adalimumab) biosimilar
31 January 2022 - Yuflyma brings a new offering to healthcare practitioners and their patients with inflammatory diseases in Canada.
Celltrion Healthcare Canada is very pleased to announce that Health Canada granted a notice of compliance on 24 December 2021 for Yuflyma, a high concentration (100 mg/mL), low volume, citrate free and latex-free biosimilar to Humira (adalimumab).
Yuflyma is approved across all ten intended indications for the treatment of multiple chronic inflammatory diseases, including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, adult ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, adult uveitis and paediatric uveitis.
